1. Introduction {#sec1-nutrients-11-00901}
===============

The microbiota that inhabits the human gut is part of an extremely complex ecological system. These microorganisms interact not only with each other, but also with their host in a symbiotic relationship \[[@B1-nutrients-11-00901]\]. The imbalance in the composition of gut microbiota, a condition known as dysbiosis, has negative health consequences. Several diseases have been linked to dysbiosis, including atopic dermatitis, inflammatory bowel disease, diabetes, obesity, cancer and, recently, neuropathology \[[@B2-nutrients-11-00901],[@B3-nutrients-11-00901]\].

Due to the importance of gut microbiota in health maintenance and disease prevention, there is a growing interest in strategies capable of their modulation, for example through the ingestion of probiotics \[[@B4-nutrients-11-00901]\]. Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefit to the host \[[@B5-nutrients-11-00901]\]. Lactic acid bacteria (LAB) and bifidobacteria are the most common types of microorganisms used as probiotics, although other bacteria and certain yeasts are also used \[[@B6-nutrients-11-00901]\]. The most important strain properties to even be considered for probiotic use include resistance to gastric acidity, bile acid resistance, antimicrobial activity against potentially pathogenic bacteria or fungi and ability to reduce pathogen adhesion to surfaces \[[@B7-nutrients-11-00901]\]. In vitro studies provide the first step in evaluating probiotics and these tests ensure that the microorganism is able to withstand the conditions of gastrointestinal tract and exert their functional properties \[[@B8-nutrients-11-00901]\].

There is a growing body of evidence demonstrating an interaction between the intestinal microbiota, the gut and the central nervous system (CNS), known as the brain--gut--microbiota axis \[[@B9-nutrients-11-00901]\]. This link between the gut microbiota and CNS suggests that their modification may have applications in the treatment of neuropsychiatric disorders \[[@B10-nutrients-11-00901],[@B11-nutrients-11-00901],[@B12-nutrients-11-00901]\]. Several preclinical studies have evaluated whether manipulation of the gut microbiota through the ingestion of probiotics can affect behaviour in animals. They have shown that probiotics may be used to modulate behaviours related to psychiatric disorders, including depressive-like behaviour \[[@B10-nutrients-11-00901],[@B13-nutrients-11-00901],[@B14-nutrients-11-00901],[@B15-nutrients-11-00901],[@B16-nutrients-11-00901],[@B17-nutrients-11-00901],[@B18-nutrients-11-00901]\]. However, the mechanisms underlying the ability of certain bacteria to modulate depressive-like behaviour remain to be elucidated.

Depression is a heterogeneous disorder with a highly variable course, and, according to the World Health Organization (WHO), it must become the biggest disabling disorder in the next 20 years \[[@B19-nutrients-11-00901]\]. Furthermore, the comorbidity of depressive disorders and anxiety is common and individuals affected by both disorders concurrently have shown reduced quality of life, and poorer treatment outcomes compared with individuals with only one disorder \[[@B20-nutrients-11-00901]\]. Currently, most pharmacological treatments for depression focus on neurotransmitter deficiency in monoaminergic synapses. However, such drugs have delayed action and may exhibit adverse side effects such as headaches, nausea, agitation, or sedation \[[@B21-nutrients-11-00901]\]. Therefore, the search for new therapeutic agents has been increasingly stimulated.

*Lactococcus* is a genus of Gram-positive LAB and the species *Lactococcus lactis* is commonly used as starter culture in the manufacture of fermented dairy products such as cheese and yogurt \[[@B22-nutrients-11-00901]\]. Certain strains of *Lactococcus lactis* subsp. *cremoris* have shown beneficial effects in animal models. Its protective action has already been demonstrated against changes induced by carbon tetrachloride, against the influenza virus and in sodium dextran sulphate-induced colitis \[[@B23-nutrients-11-00901],[@B24-nutrients-11-00901],[@B25-nutrients-11-00901],[@B26-nutrients-11-00901]\]. It is important to note that the biological effects of probiotics are strain-specific and that the success of one strain cannot be extrapolated to another strain \[[@B27-nutrients-11-00901]\].

Therefore, the objective of this study was to evaluate the probiotic characteristics and the antioxidant activity in vitro of *L. lactis* subsp. *cremoris* LL95, a LAB isolated from cheese. In addition, the safety and the possible antidepressant- and anxiolytic-like activity of this strain in mice were investigated.

2. Materials and Methods {#sec2-nutrients-11-00901}
========================

2.1. Drugs {#sec2dot1-nutrients-11-00901}
----------

Ascorbic acid, 2,4,6-Tris(2-pyridyl)-s-triazine (TPTZ) and 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were of analytical grade and obtained from standard commercial suppliers.

2.2. Bacterial Strain and Growth Conditions {#sec2dot2-nutrients-11-00901}
-------------------------------------------

*Lactococcus lactis* subsp. *cremoris* LL95 was obtained from the culture collection of the Food Microbiology Laboratory---Department of Agroindustrial Science and Technology of the Federal University of Pelotas (UFPel), Brazil. This strain was isolated from sliced mozzarella cheese sold in markets and minimarkets in Pelotas, Rio Grande do Sul, Brazil.

Sourced from frozen stocks (−80 °C), bacteria were reactivated in De Man, Rogosa and Sharpe broth (MRS broth) (Merck^®^, Darmstadt, Germany), plated in MRS agar, cultured anaerobically at 37 °C for 24 h, then inoculated in fresh MRS broth and grown at 37 °C under aerobic conditions for 24 h in 250 mL Erlenmeyer flasks containing 50 mL of MRS medium.

2.3. In Vitro Evaluation of Probiotic Characteristics {#sec2dot3-nutrients-11-00901}
-----------------------------------------------------

### 2.3.1. Survival in Simulated Gastrointestinal Tract Conditions {#sec2dot3dot1-nutrients-11-00901}

The analysis of the survival of bacteria in simulated gastrointestinal tract conditions was performed as reported by Huang and Adams \[[@B28-nutrients-11-00901]\]. Briefly, the culture was carried out in 5 mL of MRS broth and incubated at 37 °C for 24 h, followed by centrifugation at 6800× *g* for 10 min at 4 °C. The obtained pellet was washed twice with phosphate buffer saline (PBS), then resuspended in 0.5% saline. A 200 μL aliquot of the cell suspension was mixed in 300 μL of saline and 1 mL of gastric juice, with subsequent incubation at 37 °C. The simulated gastric juice consisted of 3 mg/mL pepsin (Sigma-Aldrich^®^, St. Louis, MO, USA) pH 2.5. The viable cell counts were performed initially and later at 15, 30, 60, 120, 180 and 240 min to evaluate tolerance to simulated gastric juice in plates containing MRS agar (Merck^®^) and incubated at 37 °C after 72 h. The effect of the presence of food on the survival during simulated transit in gastric juice at pH 2.5 was evaluated under the same conditions except that the saline was substituted with 10% (*w*/*v*) skimmed milk.

### 2.3.2. Evaluation of The Resistance to Different Concentrations of NaCl, pH and Bile Salts {#sec2dot3dot2-nutrients-11-00901}

The ability of bacteria to multiply at different concentrations of NaCl, pH and bile salts was analysed, as reported by Drosinos et al. \[[@B29-nutrients-11-00901]\], with some modifications. The isolate was cultured in MRS broth (Merck^®^, Darmstadt, Germany) and subsequent passage (1% v/v) of the culture for the different conditions. To test bacterial growth in the presence of salt, pH and bile salts, the MRS broth was modified with 4.5% and 6% of NaCl (Synth^®^, Diadema, Brazil), pH 2.0 (HCl) and the addition of bovine bile at 0.3% and 1% (v/v), respectively. The isolate was incubated at 37 °C for 24 h. After incubation, the cultures were transferred to agar MRS and incubated at 37 °C. The presence of growth in the medium after 24 h of incubation was considered evidence of the ability of bacteria to support the different conditions.

### 2.3.3. Autoaggregation and Coaggregation Abilities {#sec2dot3dot3-nutrients-11-00901}

The autoaggregation and coaggregation abilities of the bacteria were evaluated according to the methodology described by Collado, Meriluoto and Salminen \[[@B30-nutrients-11-00901]\]. Cell suspension was obtained from the culture of the isolate in MRS broth and the indicator microorganism in Brain Heart Infusion (BHI) (Himedia^®^, Mumbai, India) at 37 °C for 24 h. The culture was centrifuged at 6800× *g* for 10 min at 4 °C and the pellet was washed twice with PBS. Then, the cells were resuspended in 0.5% saline and absorbance at 600 nm was adjusted to 0.25 ± 0.02 for the tests.

Autoaggregation was determined by reading the absorbance (600 nm) of the cell suspensions, termed as the total bacterial suspension (time zero), and after 2, 20, and 24 h of incubation at 20 °C and 37 °C, termed as the upper suspension. The autoaggregation percentage was expressed as: autoaggregation (%) = (1 − A upper suspension/A total bacterial suspension) × 100.

To determine the coaggregation with *Listeria monocytogenes* ATCC 7644, cell suspensions were prepared as described above, incubated at 20 °C and at 37 °C alone (controls), with equal proportions of *L. lactis* LL95 and the indicator microorganism (1:1). Absorbance readings (600 nm) were taken after 0, 2, 20, and 24 h of incubation. The results were expressed in percentages as follows: coaggregation (%) = \[(At0) − (Atx)/(At0)\] × 100, where At0 represents the absorbance of the bacterial suspensions at initial time (zero) and Atx represents the absorbance of bacterial suspensions at the different times tested.

### 2.3.4. Antimicrobial Activity {#sec2dot3dot4-nutrients-11-00901}

The antimicrobial activity of *L. lactis* LL95 was tested by the spot-on-the-lawn technique, as described by Biscola et al. \[[@B31-nutrients-11-00901]\], with minor modifications, against *Escherichia coli* O157:H7 ATCC 43895, *Klebsiella pneumoniae* CCBH6603, *Listeria monocytogenes* ATCC 7644 and *Staphylococcus aureus* ATCC 25923. Briefly, aliquots of 2 μL from 24 h at 37 °C culture of *L. lactis* LL95 were spotted onto MRS agar after 24 h of incubation under anaerobic conditions at 37 °C. Then, the plates were covered with a semisolid BHI (Himedia^®^, Mumbai, India) agar containing 10^5^ CFU/mL of the indicator microorganism and incubated for 24 h at 37 °C. The plates were then analysed for the presence or absence of inhibition halos (transparency zones around the isolate). The presence of this indicated antimicrobial activity and the diameters were measured using a calliper (Digimess^®^, São Paulo, Brazil).

### 2.3.5. Antibiotic Susceptibility Tests {#sec2dot3dot5-nutrients-11-00901}

To evaluate phenotypic antibiotic susceptibility, the agar disc diffusion method was applied using MRS agar. The test was performed as described by the European Food Safety Authority \[[@B32-nutrients-11-00901]\]. Twelve antibiotics were tested: amikacin (30 μg), ampicillin (10 μg), chloramphenicol (30 μg), erythromycin (15 μg), gentamicin (10 μg), penicillin G (10 μg), trimethoprim-sulphamethoxazole (25 μg), tetracycline (30 μg), vancomycin (30 μg), clindamycin (2 μg), ciprofloxacin (5 μg) and sulphonamide (300 μg). The plates were incubated for 24 h at 37 °C. The diameters of the zones of inhibition were measured using a Digimess^®^ calliper and the results were expressed according to Liasi et al. \[[@B33-nutrients-11-00901]\] as follows: resistant (≤ 15 mm), intermediate (16--20 mm) or sensitive (≥ 21 mm).

2.4. Determination of In Vitro Antioxidant activities of *L. lactis* subsp. *cremoris* LL 95 {#sec2dot4-nutrients-11-00901}
--------------------------------------------------------------------------------------------

### 2.4.1. Preparation of Intact, Heat-Killed, and Lyophilised Cells {#sec2dot4dot1-nutrients-11-00901}

*Lactococcus lactis* LL95 was incubated in MRS broth overnight at 37 °C and intact cells were harvested by centrifugation (10000× *g*, 10 min) at 4 °C. The resulting pellets were washed twice with sterile PBS and resuspended in sterile distilled water at a final concentration 10^9^ CFU in 25, 100 or 1000 µL, according to the test to be performed. Heat-killed cells were obtained by placing the samples in a water bath at 95 °C for 30 min \[[@B34-nutrients-11-00901]\]. To obtain lyophilised cells, the samples were dehydrated by freeze-drying (Liotop, Model-L101, São Carlos, Brazil) for 24 h.

### 2.4.2. DPPH Radical Scavenging Activity Assay {#sec2dot4dot2-nutrients-11-00901}

The DPPH radical scavenging assay was performed according to Xing et al. \[[@B35-nutrients-11-00901]\]. Briefly, 1 mL of LL95 was mixed with 1 mL of DPPH solution (0.2 mM). The mixture was incubated in the dark at room temperature for 30 min. Distilled water was used for the control sample. The scavenged DPPH was then monitored by determining the absorbance at 517 nm. The radical scavenging activity was quantified using the following formula: DPPH radical scavenging activity (U/mL) = ABS~C~ − ABS~S~/S × 100, where ABS~C~ and ABS~S~ are the absorbance of the control and the test samples at 517 nm, respectively, and S is the volume (mL) of the sample. The results are expressed as DPPH radical scavenging activity (U/mL).

### 2.4.3. Scavenging of ABTS^•+^ Radical {#sec2dot4dot3-nutrients-11-00901}

The ABTS^•+^ radical scavenging assay was performed according to Han et al. \[[@B36-nutrients-11-00901]\]. Briefly, the ABTS^•+^ was diluted in a 20 mM sodium acetate buffer (pH 4.5). Posteriorly, 100 µL of LL95 samples were mixed with 3 mL of ABTS^•+^ solution and incubated in the dark at room temperature for 6 min. The absorbance of mixture was measured at 734 nm, calculated as follows: ABTS^•+^ scavenging rate (%) = (Ac − As)/Ac × 100, where A~S~ is the absorbance of the *L. lactis* LL95 sample and A~C~ is the absorbance of control (ABTS^•+^ solution without LL95 sample). The results are expressed as ABTS^•+^ scavenging rate (%).

### 2.4.4. Ferric Ion Reducing Antioxidant Power (FRAP) {#sec2dot4dot4-nutrients-11-00901}

The reducing power of LL95 was tested by the FRAP assay according to Han et al. \[[@B36-nutrients-11-00901]\] with minor modifications. Briefly, 750 µL of FRAP solution was heated to 37 °C in a water bath. Then, 25 µL of sample and 75 µL of ultrapure water were added. The mixture was placed in the dark for 5 min and the absorbance was measured at 593 nm. A standard curve was prepared with 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 mM FeSO~4~.7H~2~O. The FRAP values of samples were calculated according to the standard curve. The results were expressed as the equivalent amount of FeSO~4~ (mM).

2.5. In Vivo Experiments {#sec2dot5-nutrients-11-00901}
------------------------

The first step of knowledge on probiotic strains is conducted through in vitro assays. However, health benefits of probiotics can only be demonstrated by in vivo studies. Animal models can be used to determine the safety of probiotic microorganisms, characterise a possible mechanism of action, or convey other knowledge of probiotic strains. In this way, the in vivo safety and possible antidepressant- and anxiolytic-like effects of L. lactis subsp. cremoris LL95 in mice were evaluated.

### 2.5.1. Animals {#sec2dot5dot1-nutrients-11-00901}

The in vivo experiments were conducted using female C57BL/6 mice (20--22 g, 90 days old). Animals were maintained in an appropriate cabinet with forced air ventilation, under a 12-h light/dark cycle, at a controlled room temperature of 22 ± 2 °C, with food and water provided ad libitum. This study was approved by the Ethics Commission for Animal Use of the Federal University of Pampa (CEUA protocol \#028/2017) and the procedures used were conducted according to the guidelines of the Committee on the Care and Use of Experimental Animal Resources. This study was developed in female mice given the susceptibility of women to the development of mood disorders \[[@B37-nutrients-11-00901]\].

### 2.5.2. Experimental Procedure {#sec2dot5dot2-nutrients-11-00901}

Ninety-day-old female mice received gavage with 100 μL of sterile distilled water (control group, *n* = 6) or a daily dose of 1 × 10^9^ CFU (suspended in 100 μL sterile distilled water, once a day) freeze-dried *L. lactis* LL95 (LL95 group, *n* = 6). This procedure was carried out daily for a period of 28 continuous days \[[@B10-nutrients-11-00901]\]. At the end of the treatment, the animals underwent a series of behavioural testing, including open-field, elevated plus maze, tail suspension, and forced swim tests ([Figure 1](#nutrients-11-00901-f001){ref-type="fig"}).

### 2.5.3. Antidepressant- and Anxiolytic-Like Evaluation {#sec2dot5dot3-nutrients-11-00901}

The behavioural tests were performed from the least stressful to the most stressful, to avoid stress interference in the results. The tests were recorded using a video camera supported by a tripod and the images were analysed using ANY-maze Video Tracking System version 6.06 (Wood Dale, USA).

#### Open-Field Test (OFT)

On Day 29, the mice were introduced to an open-field apparatus (50 cm × 50 cm) made of plywood with the floor divided into sixteen squares \[[@B38-nutrients-11-00901]\]. Each animal was placed individually at the centre of the apparatus and their behaviour was monitored for 5 min. This test was carried out to assess the possible effect of the treatments on locomotor activity and to measure anxiety-like behaviour.

#### Elevated Plus Maze (EPM)

The EPM apparatus consisted of a plus-shaped made of plywood with two opposing open arms (30 cm × 8 cm) and two opposing closed arms (30 cm × 8 cm × 15 cm) connected by a central platform (8 cm × 8 cm) and elevated 120 cm above the floor. Each mouse was placed in the central platform, facing an open arm. The total arm entries and the amount of time spent by animals in the open and closed arms of the maze was measured during a 5-min period. The number of total entries, per cent of open entries (open entries/total entries × 100) and per cent of time in the open arms (time in open arms/total time of the test × 100) were determined. A reduction of the percentage of time spent and the number of entries into the open arms was considered as an anxiety-like index, independent of locomotor activity \[[@B39-nutrients-11-00901]\].

#### Tail Suspension Test (TST)

The TST was carried out according to Steru et al. \[[@B40-nutrients-11-00901]\]. In this test, mice were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of their tail. During a 6-min test period, the immobility time was scored for the last 5 min following a 1-min habituation period. The mice were considered immobile only when they hung passively and completely motionless.

#### Forced Swim Test (FST)

The FST was performed according to Porsolt et al. \[[@B41-nutrients-11-00901]\], with some modifications. In this test, individual mice were forced to swim in a vertical transparent cylinder (30 cm in height and 12 cm in diameter) containing tap water at 23 ± 1 °C with 20 cm of depth. After 1 min of habituation, the immobility time of mice was recorded for a further 5 min. The mouse was considered immobile when it remained floating motionless in the water, making only the movements necessary to maintain the head above the water. A decrease in the duration of immobility is indicative of an antidepressant-like effect \[[@B41-nutrients-11-00901],[@B42-nutrients-11-00901]\].

### 2.5.4. Hippocampus Weight and Tissue Preparation {#sec2dot5dot4-nutrients-11-00901}

The hippocampus of mice was removed and weighed using an analytical balance. The result was expressed as the relative hippocampus weight (hippocampus weight/mouse body weight). Then, the hippocampus samples were homogenised in 50 mM Tris HCl at pH 7.4, 1:5 (*w*/*v*), and centrifuged (2500× *g*, 10 min) to yield a low-speed supernatant fraction (S1). Freshly prepared S1 was used for the determination of oxidative status and antioxidant defence parameters.

### 2.5.5. Reactive Species Quantification {#sec2dot5dot5-nutrients-11-00901}

The quantification of the RS levels in the hippocampus of mice was performed according to Loetchutinat et al. \[[@B43-nutrients-11-00901]\]. Briefly, an aliquot of S1 was incubated with 1 mM DCFH-DA and 50 mM Tris-HCl pH 7.4. The oxidation of DCHF-DA to fluorescent dichlorofluorescein was measured based on the fluorescence intensity emission at 520 nm (with 480 nm excitation). The results were expressed as arbitrary units of fluorescence (UF).

### 2.5.6. Ferric Reducing Antioxidant Power (FRAP) Assay {#sec2dot5dot6-nutrients-11-00901}

The FRAP assay was performed according to Benzie and Strain \[[@B44-nutrients-11-00901]\]. This assay is based on the fact that reduction of a ferric tripyridyltriazine (Fe^III^-TPTZ) complex to the ferrous (Fe^II^-TPTZ) form at a low pH has an intense blue colour, which can be monitored by measuring the change in absorption at 593 nm. A standard curve of ascorbic acid was used, and the results were expressed as the μg equivalents of ascorbic acid.

### 2.5.7. Quantification of Faecal LAB {#sec2dot5dot7-nutrients-11-00901}

The quantification of faecal LAB was performed as reported by Grimm et al. \[[@B45-nutrients-11-00901]\], with minor modifications. Briefly, the faecal pellets of all the mice (*n* = 6) were collected at the indicated time points (Days 0 and 28), pooled, mechanically homogenised in 0.85% NaCl solution (100 mg of faeces/mL) and diluted to 10^−8^. From each dilution, 100 µl of suspension was plated in triplicate on MRS agar (Merck^®^) and incubated for 24 h at 37 °C. After incubation, the agar plates were assessed for growth, the colonies were counted and the results were expressed as CFU/100 mg faeces.

2.6. Data Presentation and Statistical Analysis {#sec2dot6-nutrients-11-00901}
-----------------------------------------------

All the results are given as the mean (s) ± standard error of means (S.E.M.). All in vitro tests were carried out in triplicate (except the antibiotic susceptibility test) and performed on the same day. The significance of the difference in mean values between more than two groups was evaluated by one-way analysis of variance (ANOVA) followed by post hoc multiple comparison by Tukey's test. For in vivo experiments, data normality was evaluated by the D'Agostino and Pearson omnibus normality test. Parametric data were analysed using the Student's *t*-test, and non-parametric data were analysed using the Mann--Whitney *U*-test. The level of *p* \< 0.05 was considered as statistically significant. Statistical analysis was performed using the GraphPad Prism statistical software (version 6.01, GraphPad Software, USA).

3. Results and Discussion {#sec3-nutrients-11-00901}
=========================

3.1. Evaluation of Probiotic Characteristics {#sec3dot1-nutrients-11-00901}
--------------------------------------------

### 3.1.1. Survival in Simulated Gastrointestinal Tract Conditions and Resistance to Different Concentrations of Salt (NaCl), pH and Bile Salts {#sec3dot1dot1-nutrients-11-00901}

An essential factor for the selection of a probiotic microorganism is the ability for it to survive and become active after entering the gastrointestinal tract. Thus, the strains must be able to survive at low pH and in the presence of digestive enzymes as well as adhere to epithelial cells to compete for the exclusion of pathogens \[[@B46-nutrients-11-00901]\]. In the evaluation of the gastric tract resistance in simulated form, it was possible to observe that the isolate was able to survive for up to 240 min in the presence of food (skimmed milk), as shown in [Table 1](#nutrients-11-00901-t001){ref-type="table"}. The presence of food and some food ingredients improved the viability of microorganisms during gastric transit; the proposed mechanism for this beneficial effect is linked to the increased pH of gastric content \[[@B47-nutrients-11-00901]\]. *Lactococcus lactis* LL95 maintained its viability above 8.2 Log CFU/mL. Even with a reduction of viable cells during in vitro simulation, the isolate may still be able to reach the intestine and promote beneficial effects if it reaches a density of around 6 Log CFU/mL \[[@B48-nutrients-11-00901]\].

One of the most important selection criteria for probiotics is the resistance to the low pH of gastric juice in the stomach and bile salts in the small intestine. Therefore, as probiotics are usually administrated orally, they must be able to survive passing through the stomach and small intestine. \[[@B8-nutrients-11-00901]\]. *Lactococcus lactis* LL95 was able to survive the different conditions of NaCl (4.5% and 6%) and bile salts (0.3% and 1%) and did not exhibit growth at pH 2. However, according to Huang and Adams \[[@B28-nutrients-11-00901]\], to survive in the gut, organisms must be tolerant to the pH of the stomach, which ranges from 2.5 to 3.5, and which can be as high as 4.5 after meals. Thus, tolerance to bile salts demonstrates that this strain is likely to be resistant to the conditions of the stomach and intestines.

### 3.1.2. Autoaggregation and Coaggregation Abilities {#sec3dot1dot2-nutrients-11-00901}

Aggregation ability has been suggested to be an important property of many bacterial strains used as probiotics \[[@B49-nutrients-11-00901]\]. The autoaggregation ability of *L. lactis* LL95 and *L. monocytogenes* ATCC 7644 is presented in [Table 2](#nutrients-11-00901-t002){ref-type="table"}. Collado et al. \[[@B30-nutrients-11-00901]\] showed that the autoaggregation of lactic acid bacteria is correlated to their adhesion ability. The coaggregation levels of probiotic bacteria with *L. monocytogenes* ATCC 7644 are shown in [Table 3](#nutrients-11-00901-t003){ref-type="table"}. The best results were observed at 37 °C and after 24 h incubation. Coaggregation of probiotic bacteria with potential gut pathogens could contribute to the positive properties of this strain. This plays a significant role, especially in the human gut, in the prevention of colonisation by pathogenic microorganisms \[[@B50-nutrients-11-00901]\]. It has been previously reported that coaggregation abilities may allow LAB strains to inhibit the growth of pathogenic strains in the gastrointestinal tract \[[@B51-nutrients-11-00901]\]. Moreover, LAB strains were found to control a microenvironment around the pathogens and increase the concentration of excreted antimicrobial substances in the process of coaggregation \[[@B50-nutrients-11-00901]\].

### 3.1.3. Antimicrobial Activity {#sec3dot1dot3-nutrients-11-00901}

*Lactococcus lactis* LL95 showed antimicrobial activity only against *L. monocytogenes* ATCC 7644, with an inhibition halo of 12 mm. The antimicrobial activity of probiotic bacteria is attributed to the production of metabolites, such as lactic and acetic acid, hydrogen peroxide, ethanol and other compounds with antimicrobial activity, beyond the bacteriocins \[[@B52-nutrients-11-00901]\]. In this respect, the most important and best characterised antimicrobials produced by LAB are lactic and acetic acid and the toxic effects of these organic acids include the reduction of intracellular pH \[[@B53-nutrients-11-00901]\]. As such, we believe that the antimicrobial activity of *L. lactis* LL95 could result from an increased rate of acidification.

### 3.1.4. Antibiotic Susceptibility Tests {#sec3dot1dot4-nutrients-11-00901}

The antibiotic resistance of microorganisms is an extremely important element to demonstrate the safety of new probiotic cultures \[[@B5-nutrients-11-00901]\]. *Lactococcus lactis* LL95 showed phenotypic resistance to amikacin, trimethoprim-sulphamethoxazole, tetracycline, clindamycin and sulphonamide ([Table 4](#nutrients-11-00901-t004){ref-type="table"}).

Antibiotic-resistant *Lactococcus strains* may be selected for environments where they are exposed to antibiotics, such as the udder of antibiotic-treated cows and, therefore, the products derived from their raw milk \[[@B54-nutrients-11-00901]\]. Once that some food and certain food supplements can introduce large numbers of live *L. lactis* into the human and animal gastrointestinal tract \[[@B55-nutrients-11-00901]\], there is the concern about the possibility of commensal bacteria acquiring antibiotic resistance genes from their environment, since this resistance could be transferred to pathogenic species, which would hamper the treatment of infections \[[@B56-nutrients-11-00901]\]. To prevent potential antibiotic resistance traits from being transferred to human or animal commensal microbiota and to pathogenic bacteria, the antimicrobial susceptibility of food-associated LAB, such as *L. lactis* strains, should be determined \[[@B57-nutrients-11-00901]\]. *Lactococcus lactis* LL95 showed sensibility to ampicillin, chloramphenicol, erythromycin, penicillin, vancomycin and ciprofloxacin ([Table 4](#nutrients-11-00901-t004){ref-type="table"}). Gad et al. demonstrated that *Lactococcus* spp. was susceptible to vancomycin and chloramphenicol and showed high resistance to tetracycline \[[@B58-nutrients-11-00901]\]. According to Teuber et al. \[[@B59-nutrients-11-00901]\], antibiotic susceptibility to ampicillin, chloramphenicol, erythromycin, gentamicin, penicillin and vancomycin is a common intrinsic characteristic of *L. lactis*.

3.2. In Vitro Antioxidant Activity Experiments {#sec3dot2-nutrients-11-00901}
----------------------------------------------

### Determination of In Vitro Antioxidant Activities of *Lactococcus lactis* subsp. *cremoris* LL95

The in vitro assays for the determination of antioxidant activity were based on the determination of the scavenging capacity against reactive oxidative species (ROS), such as superoxide anion scavenging assay, hydrogen peroxide scavenging assay and scavenging activity against stable non-biological radicals. In this study, lyophilised cells exhibited higher antioxidant activity in the in vitro assays compared to intact and heat-killed cells ([Table 5](#nutrients-11-00901-t005){ref-type="table"}). Thus, we selected lyophilised cells for the in vivo study.

Probiotics are known to have many beneficial health effects, and their consumption shows that strain-specific probiotics can present antioxidant activity and reduce damage caused by oxidation \[[@B60-nutrients-11-00901]\]. The underlying mechanism of the oxidation-resistant ability of probiotics is not yet fully understood. One of the proposed mechanisms is metal ion chelating ability, as demonstrated by Lin and Yen \[[@B61-nutrients-11-00901]\] and Lee et al. \[[@B62-nutrients-11-00901]\]. Moreover, the metabolic antioxidant activity of LAB may result from their own antioxidant enzymes (superoxide dismutase and catalase), the production of antioxidant metabolites (folate and glutathione), the up-regulation of the antioxidant activities of the host, increasing the levels of antioxidant metabolites of the host, the regulation of signalling pathways, the down-regulation activities of enzymes producing ROS and the regulation of intestinal microbiota \[[@B60-nutrients-11-00901],[@B63-nutrients-11-00901]\].

3.3. In Vivo Experiments {#sec3dot3-nutrients-11-00901}
------------------------

All mice receiving *L. lactis* LL95 remained healthy throughout the study. There were no signs of diarrhoea, weight loss or loss of appetite. Animal gain weight was not affected by probiotic treatment. The number of *L. lactis* LL95 CFU per 100 µL were determined throughout the study to ensure that the appropriate concentration was present in the aliquots of the probiotic preparation. The viability did not vary during the study period (data not shown).

### 3.3.1. *Lactococcus lactis* subsp. *cremoris* LL95 Had No Effect on Locomotor Activity and Reduced the Anxiety-Like Behaviour {#sec3dot3dot1-nutrients-11-00901}

The administration of LL95 did not affect locomotor activity in the OFT (*t* = 0.6722, df = 10; *p* = 0.5167; [Figure 2](#nutrients-11-00901-f002){ref-type="fig"}A) and in the EPM (*t* = 0.038, df = 10; *p* = 0.9704; [Figure 2](#nutrients-11-00901-f002){ref-type="fig"}E). As shown in [Figure 2](#nutrients-11-00901-f002){ref-type="fig"}B, the LL95 group remained more time in the inner zone (*t* = 2.556, df = 10; *p* = 0.0285) than the control group. In the EPM, groups differed in the percentage of entries and time spent ([Figure 2](#nutrients-11-00901-f002){ref-type="fig"}C,D) in the open arms (*t* = 2.391, df = 10, *p* = 0.0379 and *t* = 2.396, df = 10; *p* = 0.0376, respectively), suggesting anxiolytic effects.

Mice that spent significantly more time exploring the unprotected central area in the OFT apparatus demonstrated anxiolytic-like baseline behaviour, since rodents typically spend a significantly greater amount of time exploring the periphery of the arena, usually in contact with the walls \[[@B64-nutrients-11-00901]\]. Moreover, an increased activity in the open arms in the EPM also reflects an anxiolytic-like behaviour \[[@B65-nutrients-11-00901]\]. The premise that basic physiological mechanisms underlying fear in rodents can be equated to similar mechanisms operating in humans provides a degree of validity to these paradigms \[[@B66-nutrients-11-00901]\].

Several studies have demonstrated the beneficial effects of modulation of the microbiota by the use of probiotics on behaviour and brain chemistry \[[@B67-nutrients-11-00901]\]. For instance, Bravo et al. \[[@B10-nutrients-11-00901]\] showed that chronic treatment with *Lactobacillus rhamnosus* (JB-1) reduced stress-induced corticosterone and anxiety-like behaviour in normal, healthy animals. In animals subjected to 21 days of restraint stress, *Lactobacillus helveticus* NS8 supplementation increased time spent in the open arms in EPM \[[@B14-nutrients-11-00901]\]. Similarly, a recent study shows that animals that received a probiotics treatment exhibited anxiolytic-like behaviours after exposure to an unpredictable chronic mild stress (UCMS) test for four weeks \[[@B68-nutrients-11-00901]\]. Moreover, several clinical studies have demonstrated significant health benefits after consumption of probiotics, including decreased anxiety ratings and a lowered stress response in healthy volunteers, reinforcing the benefits of probiotic supplementation in the treatment of mood- and stress-related diseases \[[@B69-nutrients-11-00901],[@B70-nutrients-11-00901],[@B71-nutrients-11-00901]\].

### 3.3.2. *Lactococcus lactis* subsp. *cremoris* LL95 Reduces Depressive-Like Behaviour in Mice {#sec3dot3dot2-nutrients-11-00901}

The immobility time in the TST and FST in animals fed with *L. lactis* LL95 is shown in [Figure 3](#nutrients-11-00901-f003){ref-type="fig"}A,D, respectively. Treatment with *L. lactis* LL95 resulted in a decrease in immobility time when compared to the control group in the TST (*t* = 2.232, df = 10; *p* = 0.0497) and FST (*t* = 3.316, df = 10; *p* = 0.0078). Moreover, chronic administration of LL95 was able to increase the latency to immobility (*t* = 2.474, df = 10; *p* = 0.0329; [Figure 3](#nutrients-11-00901-f003){ref-type="fig"}B) and decrease the number of immobile episodes (*t* = 2.611, df = 10, *p* = 0.0260; [Figure 3](#nutrients-11-00901-f003){ref-type="fig"}C) in the TST.

It is believed that intestinal bacteria play a major role in the bidirectional signalling between the brain and the gut. Therefore, several studies have explored the link between gut microbiota and mood disorders, investigating the role of the gut--brain axis in the pathophysiology of depression \[[@B72-nutrients-11-00901]\]. Supporting our study, Bravo et al. \[[@B10-nutrients-11-00901]\] showed that *L. rhamnosus* (JB-1)-fed animals spent significantly less time immobile in the FST, suggesting that non-pathogenic bacteria may have beneficial effects in the treatment of depression. Furthermore, it was shown that chronic consumption of probiotic *Bifidobacterium infantis* normalised the effects of maternal separation on immobility in the FST \[[@B13-nutrients-11-00901]\]. In addition, it has been shown that, independently of diet, probiotic treatment could reduce depressive-like behaviour in the FST by 34% \[[@B17-nutrients-11-00901]\]. Akkasheh et al. \[[@B73-nutrients-11-00901]\] showed that probiotic administration in patients with major depression disorder for eight weeks had a beneficial effect on the Beck Depression Inventory and in certain metabolic profiles and biomarkers of oxidative stress.

### 3.3.3. *Lactococcus lactis* subsp. *cremoris* LL95 Increased Hippocampal Weight and Prevented Oxidative Stress in the Hippocampus in Mice {#sec3dot3dot3-nutrients-11-00901}

The weight of the hippocampus increased by 33% in female mice fed with *L. lactis* LL95 (control vs. LL95: 0.967 ± 0.109 vs. 1.467 ± 0.171; *p* = 0.0330). We observed a significant decrease in hippocampal RS levels in LL95-fed mice when compared with the control group (control vs. LL95: 103.1 ± 12.95 vs. 62.38 ± 5.27; *p* = 0.0152; [Figure 4](#nutrients-11-00901-f004){ref-type="fig"}A). In addition, the chronic administration of *L. lactis* LL95 caused an increase in the FRAP assay (*t* = 2.773, df = 10; *p* = 0.0197; [Figure 4](#nutrients-11-00901-f004){ref-type="fig"}B).

Several mechanisms are suggested as responsible for the biological activities of probiotics, one of the most debated being antioxidant activity \[[@B60-nutrients-11-00901]\]. In fact, among the beneficial effects of probiotics, protection against oxidative stress in humans and in animal models has been previously reported \[[@B74-nutrients-11-00901],[@B75-nutrients-11-00901],[@B76-nutrients-11-00901]\]. From this perspective, the selection of specific strains and the evidence of their effectiveness, resulting in the control of reactive species, can be exploited to formulate novel probiotic foods or supplements that can exert a role in the prevention of oxidative stress and related diseases.

### 3.3.4. Administration of *Lactococcus lactis* subsp. *cremoris* LL95 Increased the Faecal Content of LAB {#sec3dot3dot4-nutrients-11-00901}

As an indirect way to identify the presence of LAB in faeces, the quantification was performed in faecal pellets through plating on MRS agar. Faecal LAB counts were similar in both groups before the start of *L. lactis* LL95 administration ([Figure 5](#nutrients-11-00901-f005){ref-type="fig"}). On the 28th day, we observed that the *L. lactis* LL95 group showed an increased number of LAB CFU per 100 mg of faeces when compared to the control group (control vs. LL95: 6.0 × 10^8^ vs. 1.4 × 10^9^).

The faecal LAB count in the *L. lactis* LL95-fed group was about three times greater than that of the control group, indicating the survival of the bacteria in the gastrointestinal tract. Strains that are able to act as probiotics and can exert a protective action against infections have gained increased interest. LAB are beneficial bacteria normally associated with a balanced normal gut microbiota. They have an important role in the maintenance of health by producing antimicrobial substances, such as lactic acid, that act against pathogens, or competing for cell-surface \[[@B77-nutrients-11-00901]\]. Hence, the modulation of the microbiota gut can affect many aspects of physiology, including behaviour disorders, as demonstrated by many studies \[[@B10-nutrients-11-00901],[@B13-nutrients-11-00901],[@B78-nutrients-11-00901]\]. Thus, we believe that the high levels of LAB microbiota in the gut in the probiotic-fed group may be responsible for the positive results presented here. Evidence of the gut--brain axis and the effect of modulation of gut microbiota on mental health has shown new perspectives in determining the causative agents and possible treatments of depression- and anxiety-like disorders. Nonetheless, continuous research in this area is continuing to prove that these effects are mostly strain-specific and should not be generalised.

4. Conclusions {#sec4-nutrients-11-00901}
==============

Our findings suggest that *L. lactis* LL95 may be a potential probiotic and showed efficacy in exerting a free-radical scavenging effect. More importantly, the data of our mouse model clearly suggest the propensity of oral supplementation of *L. lactis* LL95 to improve depressive- and anxiety-like behaviour and the antioxidant parameters in the hippocampus. Although the underlying molecular mechanisms require further study, it is reasonable to speculate that the intake of this potential probiotic strain is likely to confer protective benefits in vivo against oxidative damage-mediated neurodegenerative conditions. However, we cannot exclude the possible involvement of other functional processes and systems that may contribute to the beneficial effects of *L. lactis* LL95.
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![Experimental procedure. Abbreviations: OFT, Open-Field Test; EPM, Elevated Plus Maze; TST, Tail Suspension Test; FST, Forced Swim Test.](nutrients-11-00901-g001){#nutrients-11-00901-f001}

###### 

Effect of *L. lactis* LL95 on locomotor activity and anxiety-like behaviour in the OFT and EPM. There was no difference in the distance travelled (**A**) between groups in the OFT. *L. lactis* LL95 induced an increase on the time spent in inner zone than control group (**B**). *L. lactis* LL95 induced an increased in per cent of open arms entries and per cent time spent in the open arms (**C**,**D**). The total number of entries did not differ between groups (**E**). Data are expressed as mean ± S.E.M. (*n* = 6). \* *p* \< 0.05 vs. control group.

![](nutrients-11-00901-g002a)

![](nutrients-11-00901-g002b)

![Effect of *L. lactis* LL95 on depressive-like behaviour in the TST and FST. *L. lactis* LL95 induced a decrease in the immobility time (**A**), an increase to the latency for first episode of immobility (**B**), and a decrease on immobile episodes (**C**) in TST. *L. lactis* LL95 induced a decrease in the immobility time in FST (**D**). Data are expressed as mean ± S.E.M. (*n* = 6). \* *p* \< 0.05, \*\* *p* \< 0.01 vs. control group.](nutrients-11-00901-g003){#nutrients-11-00901-f003}

![Effect of *L. lactis* LL95 in oxidative stress in hippocampus. *L. lactis* LL95 induced a decrease on levels of reactive species (**A**) and an increase in the ferric reducing/antioxidant power (**B**) on hippocampus in mice. Data are expressed as mean ± S.E.M. (n=6). \* *p* \< 0.05 vs. control group.](nutrients-11-00901-g004){#nutrients-11-00901-f004}

![Effect of *L. lactis* LL95 on faecal content of LAB. The administration of *L. lactis* LL95 induced an increase on faecal content of LAB after 28 days in mice. Data are expressed as CFU/100 mg faeces.](nutrients-11-00901-g005){#nutrients-11-00901-f005}

nutrients-11-00901-t001_Table 1

###### 

Viable cells of *Lactococcus lactis* subsp. *cremoris* LL95 when submitted to simulated gastric transit.

  -------------------------------------------
  Time\   Log CFU/mL        
  (min)                     
  ------- ----------------- -----------------
  0       8.22 ± 0.01 ^a^   8.27 ± 0.02 ^b^

  15      8.45 ± 0.04 ^a^   8.30 ± 0.00 ^b^

  30      8.23 ± 0.00 ^a^   8.38 ± 0.13 ^a^

  60      7.57 ± 0.11 ^a^   8.27 ± 0.18 ^b^

  120     5.43 ± 0.18 ^a^   8.46 ± 0.11 ^b^

  180     2.93 ± 0.31 ^a^   8.18 ± 0.00 ^b^

  240     0.57 ± 0.76 ^a^   8.25 ± 0.10 ^b^
  -------------------------------------------

The presented values are the means of three determinations ± S.E.M. Means within the same row with different letters differ significantly (*p* \< 0.05). SS: saline; SM: skim milk.

nutrients-11-00901-t002_Table 2

###### 

Autoaggregation (%) of *Lactococcus lactis* subsp. *cremoris* LL95 and *Listeria monocytogenes* ATCC 7644 during different incubation periods and temperatures.

  Time (h)   LL95               LM                                    
  ---------- ------------------ ------------------ ------------------ ------------------
  2          22.13 ± 0.12 ^a^   24.10 ± 0.14 ^b^   12.00 ± 0.15 ^a^   19.26 ± 0.31 ^b^
  20         11.70 ± 0.14 ^a^   16.80 ± 0.52 ^b^   20.18 ± 0.31 ^a^   22.72 ± 0.31 ^b^
  24         15.18 ± 0.13 ^a^   21.32 ± 0.28 ^a^   18.22 ± 0.15 ^a^   27.10 ± 0.31 ^b^

LL95: *Lactococcus lactis* subsp. *cremoris* LL95; LM, *Listeria monocytogenes* ATCC 7644. The presented values are the means of three determinations ± S.E.M. Means within the same row with different letters differ significantly (*p* \< 0.05).

nutrients-11-00901-t003_Table 3

###### 

Coaggregation (%) ability of *Lactococcus lactis* subsp. *cremoris* LL95 to *Listeria monocytogenes* ATCC 7644 during different incubation periods and temperatures.

  Time (h)   20 °C             37 °C
  ---------- ----------------- ------------------
  2          7.90 ± 0.42 ^a^   0 ± 1.98 ^b^
  20         4.95 ± 0.08 ^a^   12.73 ± 2.62 ^b^
  24         0 ± 5.49 ^a^      18.86 ± 4.44 ^b^

The presented values are the means of three determinations ± S.E.M. Means within the same row with different letters differ significantly (*p* \< 0.05).

nutrients-11-00901-t004_Table 4

###### 

Antibiotic susceptibility of *Lactococcus lactis* subsp. *cremoris* LL95.

  Antibiotics                      Inhibition Zone Diameters (mm)   Classification ^1^
  -------------------------------- -------------------------------- --------------------------
  Ampicillin                       23                               Sensitive
  Chloramphenicol                  31                               Sensitive
  Erythromycin                     23                               Sensitive
  Penicillin                       23                               Sensitive
  Vancomycin                       22                               Sensitive
  Ciprofloxacin                    29                               Sensitive
  Gentamicin                       16                               Intermediate sensitivity
  Amikacin                         15                               Resistant
  Trimethoprim-sulphamethoxazole   0                                Resistant
  Tetracycline                     15                               Resistant
  Clindamycin                      9                                Resistant
  Sulphonamide                     0                                Resistant

^1^ The interpretive criteria for the diameters of inhibition zones were those described by European Food Safety Authority \[[@B25-nutrients-11-00901]\].

nutrients-11-00901-t005_Table 5

###### 

In vitro antioxidant activities of *Lactococcus lactis* subsp. *cremoris* LL 95 on DPPH, ABTS^•+^ and FRAP assays.

  LL 95 cells         DPPH (U/mL)         ABTS^•+^ (%)       FRAP (mM)
  ------------------- ------------------- ------------------ ------------------
  Intact cells        1.30 ± 0.50 ^a^     56.50 ± 4.68 ^a^   22.40 ± 0.39 ^a^
  Heat-killed cells   6.85 ± 0.45 ^a,b^   32.34 ± 0.22 ^b^   13.49 ± 0.49 ^b^
  Lyophilised cells   9.40 ± 1.90 ^b^     79.07 ± 4.73 ^a^   45.04 ± 0.04 ^c^

The presented values are the means of three determinations ± S.E.M. Means within the same column with different letters differ significantly (*p* \< 0.05).
